Revance Therapeutics Inc (RVNC): RVNC 1Q21_revenue=$13.3M—3/31/21

Reply Private New

Replies (2) Next 10 Prev Next

Send PM Follow Ignore

Followers	827
Posts	119467
Boards Moderated	15
Alias Born	09/05/2002

DewDiligence

Re: DewDiligence post# 1777

Monday, 05/10/2021 4:19:07 PM

Monday, May 10, 2021 4:19:07 PM

RVNC 1Q21_revenue=$13.3M—3/31/21_cash=$386.8M:

https://investors.revance.com/news-releases/news-release-details/revance-reports-first-quarter-2021-financial-results-provides

No new news on the FDA manufacturing inspection for the Daxi BLA, which has been delayed by COVID travel restrictions.

1Q21 dermal-filler sales of $11.6M were up from $10.0M in 4Q20.

1Q21 cash operating expenses of $64.2M were consistent with (actually, slightly below) RVNC’s prior guidance for full-year 2021 cash operating expenses (excluding product sales and other revenue) of $270-285M.

The 3/31/21 cash balance of $386.8M was down about $50M from 12/31/20. RVNC offset some of the 1Q21 operating cash burn by selling 0.8M shares under the ATM facility, raising $21.7M.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”